No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ANVS Annovis Bio
- 4.820
- -0.530-9.91%
Close May 8 16:00 ET
- 4.900
- +0.080+1.66%
Pre 05:49 ET
53.12MMarket Cap-773P/E (TTM)
5.300High4.790Low420.36KVolume5.300Open5.350Pre Close2.10MTurnover5.16%Turnover RatioLossP/E (Static)11.02MShares22.49052wk High-6.86P/B39.30MFloat Cap4.79052wk Low--Dividend TTM8.15MShs Float132.000Historical High--Div YieldTTM9.53%Amplitude2.418Historical Low4.988Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Annovis Bio Issues Key Update on Corporate Progress
Express News | Annovis Bio - Believe FDA Will Accept Buntanetap for Symptomatic Relief,Will Allow to Continue Next Pivotal Phase III Study for Disease-Modification
Express News | Annovis Bio Inc - Will Only Enroll Patients With Early and Mild Alzheimer's (Mmse 21-28)
Express News | Annovis Bio Inc - Will Prescreen Patients for Plasma Ad Biomarkers to Confirm Diagnosis
Express News | Annovis Bio Inc - Letter to Stockholders Providing a Review of Phase II/III Data From Its Alzheimer's Study and Sharing Next Steps
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
Mon, 06 May 2024MALVERN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neur
Comments
$Annovis Bio(ANVS.US$ News that the FDA is going to clear their drug. Ran out of shares today. Borrow rate is higher than its ever been. Price movement is indicating reversal. Only 3 resistance points which are 6.20, 6.89, and 7.28.
3
$Annovis Bio(ANVS.US$ Reuters· just
Annovis Bio - Believe FDA Will Accept Buntanetap for Symptomatic Relief,Will Allow to Continue Next Pivotal Phase III Study for Disease-Modification
Annovis Bio - Believe FDA Will Accept Buntanetap for Symptomatic Relief,Will Allow to Continue Next Pivotal Phase III Study for Disease-Modification
1
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Mafiosa818 : $Ascent Solar Technologies (ASTI.US)$